3 unknown, 1 completed. 4 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Unknown 3, Completed 1 |
| Phase 2 | 3 | Unknown 3 |
Follow SciClone Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PT-112 (Phosplatin's Platinum) Combine With Gemcitabine Injection for Advanced Solid Tumors PT-112 - Biliary Tract Cancer | Phase 1 / Phase 2 | Unknown | SciClone Pharmaceuticals | 68 | 2020-04-13 | 2022-05-02 |
| An Open-label Phase I/II Clinical Trial of PT-112 Injection for Advanced Solid Tumors and Advanced Hepatocellular Carcinoma PT-112 Injection - Advanced Solid Tumors | Phase 1 / Phase 2 | Unknown | SciClone Pharmaceuticals | 125 | 2018-03-07 | 2018-03-16 |
| First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy Thymalfasin (Thymosin alpha 1, Ta1), SoC (tyrosine kinase inhibitor) - EGFR Mutation Positive Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Unknown | SciClone Pharmaceuticals | 188 | 2016-10-01 | 2016-09-19 |
| Phase I Randomized Study of CPX for the Treatment of Adult Patients With Mild Cystic Fibrosis CPX - Cystic Fibrosis | Phase 1 | Completed | FDA Office of Orphan Products Development | 35 | 1997-09-01 | 2015-03-25 |
Biliary Tract Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Cystic Fibrosis (1) · Genetic Diseases, Inborn (1) · Rare Diseases (1) · Respiratory Tract Diseases (1)
Afatinib (1) · Erlotinib Hydrochloride (1) · Gefitinib (1) · Gemcitabine (1) · Thymalfasin (1) · Trace amine-associated receptor 1 (1) · Tyrosine Kinase Inhibitors (1)
China (2) · Italy (1)
Eduardo Martins (1) · Jin Li, MD (1) · Prof. Paolo Marchetti, MD (1) · Tianshu Liu, M.D. (1)